Join
Live feed
·
PRReleasevia Quantisnow
Sana Biotechnology Inc. logo

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

ByQuantisnow·Wall Street's wire, on your screen.
SANA· Sana Biotechnology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SANA (Sana Biotechnology Inc.) and more on Quantisnow.

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform | Quantisnow